Cisplatin can damage hearing, and the loss often starts at high frequencies that patients do not notice in conversation. A baseline audiogram before the first dose, a question about ringing or muffled hearing at each cycle, and repeat audiometry when symptoms or exposure warrant it give the oncology team the information it needs to weigh the risk.
- Arrange a baseline audiogram before the first dose.
- Ask about tinnitus and muffled hearing at each cycle.
- Repeat audiometry if symptoms appear or after higher cumulative doses.
- Tell the oncologist promptly about any new loss.
Why it matters
Early high-frequency loss is silent, and the window to act on it is short.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for ent & head and neck surgery, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free